Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Ph 1 Study Long-acting Interleukin-7, Efineptakin Alfa, to Enhance Immune Reconstitution After PTCy

Phase 1 Study of Long-acting Interleukin-7, Efineptakin Alfa, to Enhance Immune Reconstitution After Post-transplantation Cyclophosphamide

This phase 1, single-center, open-label dose-escalation study will evaluate the safety, tolerability, and immune reconstitution effects of efineptakin alfa (rhIL-7-hyFc, NT-I7) administered after allogeneic hematopoietic cell transplantation (allo-HCT) in participants receiving post-transplantation cyclophosphamide (PTCy)-based graft-versus-host disease prophylaxis.

Studieoversikt

Status

Rekruttering

Studietype

Intervensjonell

Registrering (Antatt)

12

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Florida
      • Tampa, Florida, Forente stater, 33612
        • Rekruttering
        • Moffitt Cancer Center
        • Underetterforsker:
          • Melissa Alsina, MD
        • Underetterforsker:
          • Lia Perez, MD
        • Underetterforsker:
          • Doris Hansen, MD
        • Underetterforsker:
          • Rawan Faramand, MD
        • Underetterforsker:
          • Hien Liu, MD
        • Underetterforsker:
          • Omar Castaneda Puglianini, MD
        • Underetterforsker:
          • Michael Jain, MD
        • Underetterforsker:
          • Asmita Mishra, MD
        • Underetterforsker:
          • Taiga Nishihori, MD
        • Underetterforsker:
          • Nelli Bejanyan, MD
        • Underetterforsker:
          • Farhad Khimani, MD
        • Underetterforsker:
          • Aleksandr Lazaryan, MD
        • Underetterforsker:
          • Fabiana Perna, MD
        • Underetterforsker:
          • Joseph Pidala, MD
        • Underetterforsker:
          • Reshma Ramlal, MD
        • Hovedetterforsker:
          • Sayeef Mirza, MD
        • Underetterforsker:
          • Alaa Ali, MD
        • Underetterforsker:
          • Deepakbabu Chellapanian, MD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • First allogeneic HCT with peripheral blood as the only graft source used for allo HCT.
  • Diagnosis of hematologic malignancy eligible for allo-HCT.
  • Only patients with plan for post-transplant cyclophosphamide based GVHD prophylaxis are eligible.
  • Eligible donors include matched-related, matched-unrelated, mismatched unrelated, and HLA-haploidentical relatives with a shared HLA haplotype with the patient, determined by high-resolution DNA typing at HLA-A, -B, -C, and -DRB1 loci per standardof care practice as documented in the medical record.
  • Granulocyte-colony stimulating factor (G-CSF)-mobilized donor peripheral blood hematopoietic cells were targeted to a CD34+ cell dose of 5 × 106/kg with a minimum accepted dose of 2 × 106 cells per kg and a maximum dose of 10 × 106 cells per kg.
  • Patient age ≥18 years at time of consent.
  • Karnofsky performance status of ≥80% for the myeloablative and ≥60% for the nonmyeloablative (NMA) regimens.
  • Patients with documented engraftment but require granulocyte-colony stimulating factor (G-CSF) to treat myelosuppression induced by drugs used to treat or prevent infection are eligible with G-CSF washout at least 14 days prior to Efineptakin Alfa.
  • Participants must have adequate organ and marrow function
  • Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
  • Absence of dyspnea or hypoxia (< 90% of saturation by pulse oximetry on room air).
  • The effects of rh-IL-7 on the developing human fetus are unknown. For this reason and because immunomodulatory agents as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men treated or enrolled on this protocol must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for an additional four months after completion of the last study drug administration. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • Progressive or advanced hematological malignancy.
  • Patients with acute GVHD requiring systemic immunosuppression within the first 30 days (to avoid confounding lymphopenia from GVHD and steroid therapy). (Patients receiving GVHD prophylaxis will be allowed on this study).
  • Patients who fail to achieve engraftment by day 30 post-HCT (for safety concerns, and due to major interventions including second HCT done in the setting of engraftment failure).
  • History of Epstein-Barr virus (EBV) associated lymphoproliferation.
  • Active uncontrolled viral, bacterial or fungal infection.
  • History of autoimmune disease.
  • Receiving systemic corticosteroid therapy (budesonide is allowed).
  • Uncontrolled hypertension as defined by Systolic BP ≥ 160 mmHg or Diastolic BP ≥ 100 mmHg, confirmed by repeat measurement after appropriate rest.
  • Corrected QT (QTcF) prolongation (QTcF > 470 ms) or prior history of significant arrhythmia or electrocardiogram (ECG) abnormalities.
  • Presence of donor-specific antibodies.
  • Inability or unwillingness to provide signed informed consent or comply with the study requirements.
  • Participants who have not recovered from non-hematologic adverse events (AEs) due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 1), with the exception of alopecia.
  • Participants who are receiving any other investigational agents.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to rh-IL7 or other agents in the conditioning or GVHD prophylaxis regimen.
  • Participants receiving any medications or substances that are prohibited while on study (see section 6.7.). As part of the enrollment/informed consent procedures, the participant will be counseled on the risk of interactions with other agents and what to do if new medications need to be prescribed or if the participant is considering a new over-the-counter medicine or herbal product.
  • Participants with psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant or nursing women will be excluded from this study.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Efineptakin Alfa (rhIL-7-hyFc)

Participants will receive a single intramuscular dose of efineptakin alfa (NT-I7, rhIL-7-hyFc) on Day +60 after allogeneic hematopoietic cell transplantation. Dose assignment will follow a phase 1 dose-escalation design with dose levels of 240 μg/kg, 480 μg/kg, and 720 μg/kg.

Single intramuscular administration on Day +60 after allo-HCT. Dose escalation includes 240 μg/kg, 480 μg/kg, and 720 μg/kg.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Recommended phase II dose (RP2D)
Tidsramme: Up to 90 days

Determine the recommended phase 2 dose (RP2D) of efineptakin alfa.

Up to 90 days
Absolute Lymphocyte Count Recovery
Tidsramme: Up to 90 days

Proportion of participants achieving an absolute lymphocyte count (ALC) ≥1,000 cells/mm³ at Day +90 following transplantation.

Up to 90 days

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Occurrence of infections
Tidsramme: Up to 100 days

Defined as developing (or experiencing re-activation) of a viral, bacterial, or fungal infection by Day +100.

Up to 100 days

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Sayeef Mirza, MD, Moffitt Cancer Center

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. desember 2026

Primær fullføring (Antatt)

1. juni 2028

Studiet fullført (Antatt)

1. juni 2028

Datoer for studieregistrering

Først innsendt

11. november 2026

Først innsendt som oppfylte QC-kriteriene

11. november 2026

Først lagt ut (Faktiske)

17. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

17. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

11. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere